Paul Mitchell

3.1k total citations
72 papers, 1.6k citations indexed

About

Paul Mitchell is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Paul Mitchell has authored 72 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Pulmonary and Respiratory Medicine, 33 papers in Oncology and 10 papers in Molecular Biology. Recurrent topics in Paul Mitchell's work include Lung Cancer Treatments and Mutations (33 papers), Lung Cancer Diagnosis and Treatment (22 papers) and Lung Cancer Research Studies (11 papers). Paul Mitchell is often cited by papers focused on Lung Cancer Treatments and Mutations (33 papers), Lung Cancer Diagnosis and Treatment (22 papers) and Lung Cancer Research Studies (11 papers). Paul Mitchell collaborates with scholars based in Australia, United States and United Kingdom. Paul Mitchell's co-authors include Alexander Dobrovic, Thomas John, Hongdo Do, Stephen B. Fox, Puey Ling Chia, David Fielding, Michael Byrne, Bruce Robinson, G.B. Ryan and Arthur W. Musk and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer.

In The Last Decade

Paul Mitchell

70 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Paul Mitchell Australia 21 913 679 271 196 167 72 1.6k
Rasim Gucalp United States 24 628 0.7× 1.1k 1.6× 269 1.0× 116 0.6× 135 0.8× 87 1.7k
C. Zielinski Austria 15 603 0.7× 1.5k 2.3× 221 0.8× 207 1.1× 171 1.0× 51 2.0k
Cindy McGrath United States 21 316 0.3× 356 0.5× 175 0.6× 168 0.9× 269 1.6× 45 1.4k
Cleofé Romagosa Spain 20 339 0.4× 359 0.5× 379 1.4× 250 1.3× 204 1.2× 52 1.6k
Iuliana Shapira United States 20 247 0.3× 787 1.2× 244 0.9× 442 2.3× 141 0.8× 53 1.6k
A. Paloma Vizcaino France 6 518 0.6× 581 0.9× 284 1.0× 167 0.9× 517 3.1× 8 1.5k
Mary Doroshenk United States 9 287 0.3× 685 1.0× 166 0.6× 126 0.6× 232 1.4× 10 1.3k
Christian Doehn Germany 20 775 0.8× 459 0.7× 449 1.7× 235 1.2× 496 3.0× 138 1.6k
Jerri Linn Phillips United States 19 1.1k 1.2× 1.2k 1.8× 403 1.5× 276 1.4× 773 4.6× 31 2.8k
Susanne G. Warner United States 24 491 0.5× 1.1k 1.6× 251 0.9× 101 0.5× 663 4.0× 129 1.9k

Countries citing papers authored by Paul Mitchell

Since Specialization
Citations

This map shows the geographic impact of Paul Mitchell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Mitchell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Mitchell more than expected).

Fields of papers citing papers by Paul Mitchell

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul Mitchell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Mitchell. The network helps show where Paul Mitchell may publish in the future.

Co-authorship network of co-authors of Paul Mitchell

This figure shows the co-authorship network connecting the top 25 collaborators of Paul Mitchell. A scholar is included among the top collaborators of Paul Mitchell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul Mitchell. Paul Mitchell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Alexander, Marliese, Sagun Parakh, Paul Mitchell, et al.. (2024). Lurbinectedin in small cell lung cancer: real‐world experience of a multicentre national early access programme. Australasian Journal of Paramedicine. 54(7). 1087–1096. 5 indexed citations
2.
Yu, Hui, Leonid Churilov, Gareth Rivalland, et al.. (2021). NaPi2b expression in a large surgical Non-Small Cell Lung Cancer (NSCLC) cohort. Clinical Lung Cancer. 23(2). e90–e98. 6 indexed citations
3.
Leal, José Luis, Marcin Szaumkessel, Trishe Leong, et al.. (2020). NTRK and ALK rearrangements in malignant pleural mesothelioma, pulmonary neuroendocrine tumours and non-small cell lung cancer. Lung Cancer. 146. 154–159. 24 indexed citations
4.
Hardcastle, Nicholas, et al.. (2020). Credentialing of vertebral stereotactic ablative body radiotherapy in a multi-centre trial. Physica Medica. 72. 16–21. 4 indexed citations
5.
Balasubramanian, Adithya, Mark Voskoboynik, Mark Shackleton, et al.. (2020). Impact of Radiotherapy on the Efficacy and Toxicity of anti-PD-1 Inhibitors in Metastatic NSCLC. Clinical Lung Cancer. 22(3). e425–e430. 16 indexed citations
6.
Mazza, Danielle, Xiaoping Lin, Jon Emery, et al.. (2019). MA22.06 Longer Lung Cancer Time Intervals Amongst Culturally and Linguistically Diverse Patient Than Anglo-Australian Patients. Journal of Thoracic Oncology. 14(10). S340–S341. 1 indexed citations
7.
8.
Thapa, Bibhusal, Adriana Salcedo, Xihui Lin, et al.. (2017). The Immune Microenvironment, Genome-wide Copy Number Aberrations, and Survival in Mesothelioma. Journal of Thoracic Oncology. 12(5). 850–859. 73 indexed citations
9.
Staplin, Natalie, Jonathan Emberson, Colin Baigent, et al.. (2014). CANCER AND CHRONIC KIDNEY DISEASE: AN INDIVIDUAL PATIENT DATA META-ANALYSIS OF 33,618 PARTICIPANTS. Oxford University Research Archive (ORA) (University of Oxford). 3 indexed citations
10.
11.
Chia, Puey Ling, Thomas John, Alexander Dobrovic, & Paul Mitchell. (2014). Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors. Clinical Epidemiology. 6. 423–423. 143 indexed citations
12.
Chouaïd, C., Jason Agulnik, Erdem Göker, et al.. (2013). Health-Related Quality of Life and Utility in Patients with Advanced Non–Small-Cell Lung Cancer: A Prospective Cross-Sectional Patient Survey in a Real-World Setting. Journal of Thoracic Oncology. 8(8). 997–1003. 115 indexed citations
13.
Eberhardt, Wilfried, Paul Mitchell, Joan H. Schiller, et al.. (2013). Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced non–small cell lung cancer. Investigational New Drugs. 32(1). 123–134. 4 indexed citations
14.
15.
Arulananda, Surein, et al.. (2011). Bronchoepidural Fistula in a Man with Actinomycosis Complicated Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 6(10). 1761–1762. 1 indexed citations
16.
Mitchell, Paul, A. Broad, Mark Rosenthal, et al.. (2011). Randomized phase 2 sequencing and pharmacokinetic study of gemcitabine and oxaliplatin in advanced non‐small cell lung cancer. Asia-Pacific Journal of Clinical Oncology. 7(4). 376–384. 1 indexed citations
17.
18.
Yap, Kenneth, Salvatore U. Berlangieri, Aurora Poon, et al.. (2005). Positron emission tomography with selected mediastinoscopy compared to routine mediastinoscopy offers cost and clinical outcome benefits for pre-operative staging of non-small cell lung cancer. European Journal of Nuclear Medicine and Molecular Imaging. 32(9). 1033–1040. 16 indexed citations
19.
Mitchell, Paul. (2001). The Development of Quality Obligations in Sale of Goods. Research Portal (King's College London). 117. 645–663. 2 indexed citations
20.
Mitchell, Paul, Roger A’Hern, Cyril Fisher, et al.. (1999). Treatment of nondysgerminomatous ovarian germ cell tumors. Cancer. 85(10). 2232–2244. 74 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Rasim Gucalp Breakdown of academic impact, for papers by C. Zielinski Breakdown of academic impact, for papers by Cindy McGrath Breakdown of academic impact, for papers by Cleofé Romagosa Breakdown of academic impact, for papers by Iuliana Shapira Breakdown of academic impact, for papers by A. Paloma Vizcaino Breakdown of academic impact, for papers by Mary Doroshenk Breakdown of academic impact, for papers by Christian Doehn Breakdown of academic impact, for papers by Jerri Linn Phillips Breakdown of academic impact, for papers by Susanne G. Warner
Rankless by CCL
2026